|
|
| |
Thursday, 2 March
2017 | ArabMedicare.com | Staff Reporter
|
|
|
| |
|
|
| |
CPhI expands in Middle
East & Africa with Abu Dhabi
event in 2018
(Amsterdam) -
UBM EMEA announces the
rebranding and relocation of
CPhI Istanbul into CPhI
Middle East & Africa, which
will open next year (3-5
September 2018) at ADNEC
Centre, Abu Dhabi, United
Arab Emirates (UAE). It
builds on the success of the
iconic CPhI brand in the
region and represents a
natural evolution to better
represent attendees.
The event is designed to
increase partnerships,
business opportunities and
meet the needs of the entire
region, which imports large
quantities of ingredients,
and relies on a network of
distributors and advanced
finished dose manufacturers
– increasingly important as
generics consumption rises.
The pharma market in the
MENA (Middle East and North
Africa) economies are a
mixture of developed,
high-income healthcare
systems, coupled with high
growth regions in North
Africa. Total pharma sales
are an impressive $32bn –
Middle East countries
account for $21.3bn
(€19.2bn) and North Africa
$10.7bn (€9.7bn) – with a
compound annual growth rate
of 7% predicted through to
2020. Collectively, with
rapidly increasing pharma
sales in many gentrifying
African nations, along with
high per capita spends and
universal healthcare in
Middle East countries the
region offers a robust
opportunity for pharma
expansion.
“CPhI Istanbul has been a
huge success since its
launch just 5 years ago,
growing to nearly 5,000
attendees, which is clear
testament to the interest
and developments in pharma
regionally. Relocating the
event to Abu Dhabi in 2018
is a natural progression. It
will attract the same
audiences from Turkey and
neighboring countries, with
the new location also
bringing in an increased
number of affluent and high
growth exhibitors and
attendees from the Middle
East and Africa” commented
Andreas Mavrommatis,
Marketing Director at UBM
EMEA.
The event will attract
leaders and key decision
makers of the pharma
industry from the Middle
East and Africa, bringing
the expertise and reach of
the CPhI brand to the heart
of this new pharma hub.
Running alongside the
exhibition, there will be
content sessions on the
latest trends, keynote
addresses, and numerous
networking opportunities.
CPhI Middle East & Africa
2018 comes with the backing
of regional government and
pharma associations, and is
expected to attract 200
local, regional and
international exhibitors
from 30 countries and 5,000
attendees.
Co-located events will
include ICSE, P-MEC,
Innopack and FDF providing
the opportunity to meet with
regional drug manufacturers,
suppliers of pharma
ingredients, distributors,
finished dose manufacturers,
and companies involved in
pharma machinery, packaging
and contract services.
The finished dose
formulation sector is
expanding quickly in the
Middle East, in particular,
with a number of plants
being commissioned in the
last few years. In the UAE,
the Government also gives
fast track approval to
locally manufactured drugs,
which is helping establish a
new manufacturing base in
the country – with the added
potential for exports to the
Gulf Cooperation Council.
“CPhI has done extremely
well in the past few years
cementing its global
influence in the MENA
region. But relocation
accelerates this
development, providing a
more central location in the
Middle East and increasing
the potential to attract new
audiences. Many of the
world’s largest pharma
companies have regional
headquarters in the United
Arab Emirates and such is
the pace of developments in
the Middle Eastern and
African economies, we expect
this to be one of the
fastest growing events in
global pharma”, concluded
Orhan Caglayan, Brand
Director CPhI Middle East &
Africa at UBM EMEA.
Related Links:
CPhl Middle East & Africa
PRINT
THIS ARTICLE
|
|
|
|
|
|
|
13-15 November 2017
United Arab Emirates
|
